LIVE TV
LIVE TV
LIVE TV
Home > World > BRIEF-Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc

BRIEF-Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc

Written By:
Published: October 19, 2026 03:44:12 IST

Add NewsX As A Trusted Source

Oct 18 (Reuters) – Zentalis Pharmaceuticals, Inc. : * ZENTALIS PHARMACEUTICALS ANNOUNCES FIRST OVERALL SURVIVAL DATA FOR AZENOSERTIB FROM DENALI PART 1B PUBLISHED IN ESMO CONGRESS 2026 ABSTRACT *

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

RELATED News

LATEST NEWS